Today’s Stock Market in 2-Minutes
November 13, 2026
November 13, 2026
November 13, 2026
November 13, 2026
November 13, 2026
Watch the replay of Axe Compute's Second Quarter 2026 earnings conference call, originally held live on Monday, August 17, 2026 at 8:30 a.m. Eastern Time. Christopher Miglino, Chief Executive Officer; Kyle Okamoto, President; and Jeremy Yaukey-Witter, Chief Financial Officer, review the Company's Q2 2026 financial results, recent business developments, and priorities for the second half of 2026. Key highlights discussed on the call: Revenue grew more than 90x sequentially in the Company's first full quarter of compute operations Customer prepayments grew from $0.8 million to $60.8 million, with $17.4 million in operating cash flow in the first half of 2026 The $260 million dedicated cluster of 2,304 NVIDIA B300 GPUs progressed through build, targeted for Q3 2026 go-live Total 2026 signed contracted value now exceeds $3 billion Read the full press release and financial statements on Axe Compute's investor website.
August 17, 2026PALO ALTO, Calif., Aug. 15, 2024 /PRNewswire/ — Mega Matrix Corp. (“MPU” or the “Company”) (NYSE American: MPU), today announced that it launched its Japanese-language short drama “ドS社長と死にゆく奥様の百日戦争” on August 13th at FlexTV. The intense emotional confrontations in the drama are like sharp lancet blades, precisely dissecting the dark sides of the characters’ inner selves. This compels the audience […]
August 15, 2024
VANCOUVER, British Columbia, Nov. 13, 2026 (GLOBE NEWSWIRE) — Equity Insider News Commentary – Building a gold mine runs on milestones: permits, money, steel on site and, eventually, the first pour. Four companies reported where their builds stand over the past two months, from a West African mine that has just poured first gold to a Tanzanian project […]
November 13, 2026
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2026 (GLOBE NEWSWIRE) — Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced the pricing of an underwritten offering of 1,894,540 shares of its […]
November 13, 2026
– Pivotal Phase 3 ENSURE-1 and ENSURE-2 Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis Remain on Track, with Top-Line Data Expected in December 2026 – – Initiation of Phase 3 PROTECT-MS Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis Ongoing, with First-Patient-Enrolled Expected in the First Half of 2027 – – Executive Leadership Team […]
November 13, 2026
November 13, 2026
November 13, 2026
November 13, 2026
November 13, 2026
November 13, 2026
November 13, 2026
November 13, 2026
November 13, 2026